Correlation Between Cadrenal Therapeutics, and ABVC Biopharma
Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and ABVC Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and ABVC Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cadrenal Therapeutics, Common and ABVC Biopharma, you can compare the effects of market volatilities on Cadrenal Therapeutics, and ABVC Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of ABVC Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and ABVC Biopharma.
Diversification Opportunities for Cadrenal Therapeutics, and ABVC Biopharma
0.04 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Cadrenal and ABVC is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and ABVC Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ABVC Biopharma and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with ABVC Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ABVC Biopharma has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and ABVC Biopharma go up and down completely randomly.
Pair Corralation between Cadrenal Therapeutics, and ABVC Biopharma
Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 1.63 times more return on investment than ABVC Biopharma. However, Cadrenal Therapeutics, is 1.63 times more volatile than ABVC Biopharma. It trades about 0.18 of its potential returns per unit of risk. ABVC Biopharma is currently generating about -0.31 per unit of risk. If you would invest 1,627 in Cadrenal Therapeutics, Common on November 10, 2024 and sell it today you would earn a total of 243.00 from holding Cadrenal Therapeutics, Common or generate 14.94% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cadrenal Therapeutics, Common vs. ABVC Biopharma
Performance |
| Timeline |
| Cadrenal Therapeutics, |
| ABVC Biopharma |
Cadrenal Therapeutics, and ABVC Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cadrenal Therapeutics, and ABVC Biopharma
The main advantage of trading using opposite Cadrenal Therapeutics, and ABVC Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, ABVC Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will offset losses from the drop in ABVC Biopharma's long position.The idea behind Cadrenal Therapeutics, Common and ABVC Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| ABVC Biopharma vs. Indaptus Therapeutics | ABVC Biopharma vs. Pasithea Therapeutics Corp | ABVC Biopharma vs. Forte Biosciences | ABVC Biopharma vs. Akari Therapeutics PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Complementary Tools
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |